Immunopharmacology of CpG oligodeoxynucleotides and ribavirin
J Vollmer, R Rankin, H Hartmann, M Jurk… - Antimicrobial agents …, 2004 - Am Soc Microbiol
J Vollmer, R Rankin, H Hartmann, M Jurk, U Samulowitz, T Wader, A Janosch, C Schetter…
Antimicrobial agents and chemotherapy, 2004•Am Soc MicrobiolTo investigate their potential mechanisms of action, the nucleoside analogue ribavirin and a
TLR9 agonist were compared. The CpG oligodeoxynucleotides (ODN) demonstrated strong
TLR9-related Th1-type effects, and ribavirin appeared only to mediate signaling in TLR-
transfected cells. CpG ODN represent a promising new type of therapeutic drug for hepatitis
C or other infectious diseases.
TLR9 agonist were compared. The CpG oligodeoxynucleotides (ODN) demonstrated strong
TLR9-related Th1-type effects, and ribavirin appeared only to mediate signaling in TLR-
transfected cells. CpG ODN represent a promising new type of therapeutic drug for hepatitis
C or other infectious diseases.
Abstract
To investigate their potential mechanisms of action, the nucleoside analogue ribavirin and a TLR9 agonist were compared. The CpG oligodeoxynucleotides (ODN) demonstrated strong TLR9-related Th1-type effects, and ribavirin appeared only to mediate signaling in TLR-transfected cells. CpG ODN represent a promising new type of therapeutic drug for hepatitis C or other infectious diseases.
American Society for Microbiology